AstraZeneca Plc (ADR) (NYSE:AZN), in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world’s largest meeting of cancer doctors. AstraZeneca plc (ADR) (NYSE:AZN) stock performance was -0.83% in last session and finished the day at $72.76. Traded volume was 5.14million shares in the last session and the average volume of the stock remained 5.04million shares. The beta of the stock remained 0.50.

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has finally put a full-stop on the rumors that were spreading like fire in the industry. As per the rumors, it was expected that Shire PLC (ADR) (NASDAQ:SHPG) was considering to buy NPS Pharmaceuticals. NPS made it clear that it has not received any offer from Shire. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) dropped -0.95 percent to $32.29 Tuesday on volume of 5.34million shares. The intra-day range of the stock was $31.50 to $33.79. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) has a market capitalization of $3.43billion.

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on June 2 announced longer-term follow up from its Phase 1 and pivotal Phase 2 trials of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The studies now show that with a median follow-up of 42.5 months for chronic-phase CML (CP-CML) patients in the Phase 1 trial, Iclusig continues to demonstrate anti-leukemic activity in those who had limited treatment options, and that deep and durable responses have been maintained in CP-CML patients in the PACE trial with 87% estimated to remain in major cytogenetic response (MCyR) at two years. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on June 03, 2014 reported a decrease of -3.60% to the closing price of $6.69. Its fifty two weeks range is $2.15 -$23.00. The total market capitalization recorded $1.25billion. The overall volume in the last trading session was 7.08million shares. In its share capital, ARIA has 186.80million outstanding shares.

Gilead Sciences Inc. (NASDAQ:GILD) announced updated interim results of a Phase 2 study (Study 102) evaluating GS-9973, its investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). In this study, single-agent treatment with GS-9973 achieved an overall response rate of 49%, with an estimated progression-free survival (PFS) rate at 24 weeks of 70%. On Tuesday, shares of Gilead Sciences, Inc. (NASDAQ:GILD) advanced 1.23% to close the day at $82.55. Company return on investment (ROI) is 18.70% and its monthly performance is recorded as 6.23%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly revenue growth is -0.47%.